Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NovaBridge Biosciences ( (NBP) ) just unveiled an announcement.
On December 10, 2025, NovaBridge Biosciences presented positive data from a Phase 1 dose expansion study of ragistomig, a bispecific antibody, at the ESMO-IO Congress. The study showed that the new Q6W dosing schedule for ragistomig demonstrated encouraging anti-tumor efficacy and improved safety compared to the previous Q2W schedule, with only 5% of patients experiencing significant liver function elevation. This advancement supports further development into combination studies, potentially enhancing treatment outcomes for patients with relapsed or refractory solid tumors. The findings align with NovaBridge’s strategy to partner globally for transformative therapies, reinforcing its position in the biotechnology industry.
The most recent analyst rating on (NBP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.
Spark’s Take on NBP Stock
According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on NBP stock, click here.
More about NovaBridge Biosciences
NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines. The company specializes in developing breakthrough therapies, with a pipeline led by givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB, and VIS-101, a bifunctional biologic targeting VEGF-A and ANG2. NovaBridge collaborates with ABL Bio on the development of ragistomig, a bispecific antibody for solid tumors, and holds rights to uliledlimab, an anti-CD73 antibody targeting cancer-related immunosuppression.
Average Trading Volume: 1,233,014
Technical Sentiment Signal: Buy
Current Market Cap: $318.4M
See more data about NBP stock on TipRanks’ Stock Analysis page.